trial · primary record
Cyclophosphamide
Relapsed and/or Refractory B-cell Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 247 |
| Primary completion | 2030-02 |
| Primary endpoint | Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753 |
| Registry ID | NCT04989803 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:50.091Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04989803
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- CYCLOPHOSPHAMIDE · approval
- CYCLOPHOSPHAMIDE · approval
- CYCLOPHOSPHAMIDE · approval
- Cyclophosphamide · compound